This presentation reviews the multidisciplinary approach to bladder preservation with tri-modality therapy for bladder cancer. We consider the quality of life implications of allowing patients to retain their native bladder and consider how disease outcomes compare to removal of the bladder with radical cystectomy. We discuss appropriate patient selection for this important, curative treatment option for patients with muscle invasive bladder cancer.
Continuing Education Instructions and Disclosure Information:
Contact hours available until 10/11/22.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation. You will be able to print your CNE certificate at any time after you complete the evaluation.
Faculty, Planners, and Speakers Conflict of Interest Disclosure:
Planning Committee Disclosures: There are no Planning Committee disclosures to declare.
Speakers Conflict of Interest Disclosure: There are no speaker disclosures to declare.
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: Society of Urologic Nurses and Associates (SUNA) is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
The SUNA accreditation is reciprocal in the states and specialty organizations that recognize the ANCC-COA accreditation process. SUNA is also a provider approved by the California Board of Registered Nursing, Provider Number CEP 5556. Accreditation and approved provider status of CE in nursing does not imply ANCC-COA approval or endorsement of any product, advertising, or educational content. SUNA urges all participants to be aware of the CE requirements for re-licensure in the states in which they hold a license.
Learning Outcome: After completing this education activity, the learner will be able to identify appropriate candidates for trimodality therapy for muscle invasive bladder cancer, and better understand the quality of life and disease outcome implications of this treatment relative to radical cystectomy.
MD, MS, MPH,
University of North Carolina, Chapel Hill